Zydus Lifesciences Limited (ZYDUSLIFE) — Financial Results | 20 May 2025(3 announcements)

Zydus Lifesciences reported net profit of ₹87.22 crores for Q4 FY2025, a 32% YoY increase from ₹65.98 crores in Q4 FY2024, driven by strong revenue growth to ₹1,250 crores (+18% YoY). The company highlighted improved operational efficiency and margin expansion as key growth drivers, with no new risks disclosed in the filing.

Zydus Lifesciences reported FY25 revenue of ₹2,32,415 crores, up 19% YoY, with net profit at ₹47,451 crores, up 23% YoY. EBITDA reached ₹70,585 crores, up 31% YoY, and EBITDA margin improved to 30.4% from 27.5%. The company declared a dividend of 1100% and highlighted strong US formulations growth of 27.2% YoY. Cash position stood at ₹48,836 crores net cash. The Board approved the audited results and recommended the dividend following a meeting on May 20, 2025.

{ "summary": "Zydus Lifesciences reported a 18% YoY revenue increase to ₹65,279 crores for Q4 FY25, driven by double-digit growth across India, US, and international markets. EBITDA margin expanded to 32.6%, up 310 bps YoY, while net cash rose to ₹48,836 crores. Capex reached ₹3,202 crores for the quarter. The company highlighted sustained market outperformance in its branded formulations business and robust volume growth in Consumer Wellness. Forward-looking statements in the presentation cover expansion plans, regulatory approvals, and innovation initiatives.", "extractedFields": { "keyEvent": "Q4 FY25 revenue grew 18% YoY to ₹65,279 crores with EBITDA margin at 32.6%", "whatChanged": "Revenue increased 18% YoY; EBITDA margin rose 310 bps to 32.6%; net cash grew to ₹48,836 crores; Capex was ₹3,202 crores", "forwardGuidance": "The company plans to expand Medtech through acquisition of Amplitude Surgical and advance NCE development including Saroglitazar Magnesium for PBC and MASH, with NDA filing expected for a new oncology product in 2026", "investorTakeaway": "Strong revenue and margin growth across all segments signal robust operational momentum and improved cash generation for shareholders", "sentiment": "positive" }